We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Wants Revised Labeling for Anti-Seizure Drug Zonegran
FDA Wants Revised Labeling for Anti-Seizure Drug Zonegran
February 27, 2009
Eisai’s anti-seizure drug Zonegran, and generic formulations of the treatment, may cause metabolic acidosis in some patients, according to an FDA MedWatch alert.